•
AR
ARDX
Ardelyx, Inc.
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
1.94B
Volume
8.11M
52W High
$8.17
52W Low
$3.21
Open
$0.00
Prev Close
$7.76
Day Range
0.00 - 0.00
About Ardelyx, Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cable One, Inc. - CABO
GlobeNewswire Inc.•Jun 2
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025
GlobeNewswire Inc.•May 21
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
GlobeNewswire Inc.•Apr 24
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference
GlobeNewswire Inc.•Feb 19
Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.•Jan 6
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
GlobeNewswire Inc.•Nov 5
ARDX DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important October 15 Deadline in Securities Class Action – ARDX
GlobeNewswire Inc.•Oct 13
SHAREHOLDER ALERT: Holzer & Holzer, LLC Reminds Investors of the October 15, 2024 Lead Plaintiff Deadline in Class Action Lawsuits Filed on Behalf of Symbotic Inc. (SYM), Ardelyx, Inc. (ARDX), PDD Holdings Inc. (PDD), and Sprinklr, Inc. (CXM) Shareholders
GlobeNewswire Inc.•Oct 8